Glutathione-activated biotin-targeted dual-modal imaging probe with improved PDT/PTT synergistic therapy

Glutathione (GSH), a highly abundant thiol compound within cells, plays a critical role in physiological processes and exhibits close correlation with cancer. Among molecular imaging technologies, most probes have relatively short emission wavelengths and lack photoacoustic imaging (PA) capability,...

Full description

Saved in:
Bibliographic Details
Published in:Analytica chimica acta 2024-08, Vol.1316, p.342860, Article 342860
Main Authors: Yang, Zhi-Chao, Gu, Qing-Song, Chao, Jing-Jing, Tan, Fang-Yuan, Mao, Guo-Jiang, Hu, Liufang, Ouyang, Juan, Li, Chun-Yan
Format: Article
Language:English
Subjects:
Dual-modal imaging
Glutathione
Photodynamic therapy
Photothermal therapy
Tumor-targeting ability
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glutathione (GSH), a highly abundant thiol compound within cells, plays a critical role in physiological processes and exhibits close correlation with cancer. Among molecular imaging technologies, most probes have relatively short emission wavelengths and lack photoacoustic imaging (PA) capability, resulting in the inability to obtain tissue images with high penetration depth. The presence of GSH in the tumor microenvironment neutralizes ROS, diminishing the therapeutic effect of PDT, thus resulting in often unsatisfactory therapeutic efficacy. Therefore, it is imperative to develop a dual-modal probe for the detection of GSH and the diagnosis and treatment of cancer. In this study, we synthesized a novel dual-modal probe, Cy-Bio-GSH, utilizing near-infrared fluorescence (NIRF) and photoacoustic (PA) imaging techniques for GSH detection. The probe integrates cyanine dye as the fluorophore, nitroazobenzene as the recognition moiety, and biotin as the tumor-targeting moiety. Upon reacting with GSH, the probe emits NIR fluorescence at 820 nm and generates a PA signal. Significantly, this reaction activates the photodynamic and photothermal properties of the probe. By depleting GSH and employing a synergistic photothermal therapy (PTT) treatment, the therapeutic efficacy of photodynamic therapy (PDT) is remarkably enhanced. In-vivo experiments confirm the capability of the probe to detect GSH via NIRF and PA imaging. Notably, the combined tumor-targeting ability and PDT/PTT synergistic therapy enhance therapeutic outcomes for tumors and facilitate their ablation. A novel tumor-targeting and dual-modal imaging probe (Cy-Bio-GSH) is synthesized, exhibiting remarkable sensitivity and selectivity to GSH, enabling the visualization of GSH in cells and the differentiation between normal and cancer cells. Cy-Bio-GSH enhances PDT/PTT with effective killing of cancer cells and makes the ablation of tumors in mice. This work represents the first tumor-targeting probe for GSH detection, and provides crucial tool for cancer diagnosis and treatment by dual-modal imaging with improved PDT/PTT synergistic therapy. [Display omitted] •A tumor-targeting and dual-modal imaging probe (Cy-Bio-GSH) is synthesized.•Cy-Bio-GSH exhibits remarkable sensitivity and selectivity to glutathione (GSH).•Cy-Bio-GSH can visualize GSH in cells and differentiate normal and cancer cells.•The probe enhances synergistic PDT/PTT with good killing ability of cancer cells.•Cy-Bio-GSH with tumor-target
ISSN:0003-2670
1873-4324
1873-4324
DOI:10.1016/j.aca.2024.342860